DocumentsDate added
CASE REPORT
Rakhee Modak,Amit Mhapuskar,Darshan Hiremutt,Manjula Hebbale,Shubhangi Gaikwad
Department of Oral Medicine and Radiology, Bharati Vidyapeeth Deemed University Dental College and Hospital,Pune, India
Address reprint requests to:
*Dr Rakhee Modak,
Department of Oral Medicine and Radiology,Bharati Vidyapeeth Deemed University Dental College and Hospital, Pune, India
Article citation: Modak R, Mhapuskar A, Hiremutt D, Hebbale M, Gaikwad S. Arteriovenous malformation of the oral cavity: a case report and review of literature.J Pharm Biomed Sci 2016;06(09):514–517.
Abstract
Arteriovenous malformations (AVMs) are developmental vascular anomalies that occur when the embryonic vascular network fails to differentiate. It is composed of abnormal communications between arteries and veins without a normal intervening capillarybed.
Lymphatic, capillary, venous and AV malformations make up a majority of vascular malformations.
Facial vascular malformations can cause dental emergencies that result in fatal or life threatening and disfiguring situations. Diagnosis of these lesions is essential and management of maxillofacial AVMs remains challenging. In this article, we report a case of intra-oral AV malformation of 16-year-old male patient that was treated with sclerotherapy using 1% sodium tetradecyl sulfate as sclerosant. The treatment was effective,within a short period of time after injection and no recurrence was observed one year postoperatively.
KEYWORDS arteriovenous malformation, vascular malformation, sclerotherapy, developmental anomaly
REFERENCES
1.Kennedy KS. Arteriovenous malformation of the maxilla. Head Neck. 1990;12:512–515.
2.Glowacki J, Mulliken JB. Mast cells in hemangiomas and vascular malformations. Pediatrics. 1982;70:48–51.
3.Kelly DE, Terry BC, Small EW. Arteriovenous malformation of the mandible: report of case. J Oral Surg. 1977;3:387–93.
4.Finn MC, Glowacki J, Mulliken JB. Congenital vascular lesions: clinical application of a new classification. J Pediatr Surg.1983;18:894–99.
5.Burrows PE, Lasjaunias PL, TerBrugge KG, Flodmark O. Urgent and emergent embolization of lesions of the head and neck in children: indications and results. Pediatrics. 1987;80:386–94.
6.Garzon MC, Huang JT, Enjolras O, Frieden IJ. Vascular malformations.Part 1. J Am Acad Dermatol. 2007;56:353–370.
7.Hayward JR. Central cavernous hemangioma of the mandible: report of four cases. J Oral Surg. 1981;39:526–32.
8.Anderson JH, Grisius RJ, McKean TW. Arteriovenous malformation of the mandible. Oral Surg Oral Med Oral Path. 1981;52:118–125.
9.Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg. 1982;69:412–22.
10.Kaban LB, Mulliken JB. Vascular anomalies of the maxillofacial region. J Oral Maxillofac Surg. 1986;44:203–13.
11.Spatz S, Kaltman S, Farber S. Vascular malformation: report of a case with eight-year follow up. J Oral Maxillofac Surg. 1985;43:281–84.
12.Kim JY, Kim DI, Do YS, Lee BB, Kim YW, Shin SW, et al. Surgical treatment for congenital arteriovenous malformation: 10 years’ experience. Eur J Vasc Endovasc Surg. 2006;32:101–6.
13.Biller HF, Krespi YP, Sore PM. Combined therapy for vascular lesions of the head and neck with intra-arterial embolization and surgical excision. Otolaryngol Head Neck Surg. 1982;90:37–47.
14. Brooks B. Treatment of traumatic arteriovenous fistula. South Med J.1930;23:100–6 .
15. Macansh JD, Owen MD. Central cavernous hemangioma of the mandible: report of cases. J Oral Surg. 1972;30:293–296.
16. El-Sheikh MM, Zeitdoun IM, El-Massry M, Medra AM. Vascular malformation of the jaw bones: report on nine patients.J Craniomaxillofac Surg. 1993;21:9–14.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Original article
Rampalliwar Sanjeev1,Rajak Chanda1*,Singh Prabhaker2
1Department of Physiology, S. S. Medical College, Rewa, Madhya Pradesh, India
2Department of Pharmacology, S. S. Medical College, Rewa, Madhya Pradesh, India
Address reprint requests to:
*Dr Rajak chanda,
Department of Physiology, S. S. Medical College, Rewa, Madhya Pradesh, 486001, India
Article citation: Sanjeev R, Chanda R,Prabhaker S. Can 6-week practice of Hasya Yoga reduce the cardiovascular hyper-reactivity and other cardiac parameters?. J Pharm Biomed Sci 2016;06(09):508–513.Available at www.jpbms.info
Abstract
Laughter has been used as a therapeutic tool for many years because it is a natural form of medicine. Decades of scientific research had already proven that laughter has a documented
positive impact as a form of complementary preventive and therapeutic medicine.The basic concept with Laughter Yoga is that our body cannot differentiate between real or artificial laughter, hence accords all the benefits of real laughter. The aim of the present study was to investigate whether regular practice of Hasya Yoga for 6 weeks can reduce the cardiovascular hyper-reactivity and other cardiac parameters in healthy young medical students. The study group comprises 40 healthy young medical students of 18–23 years age group. At the start of the study, there were 18 hyper-reactors to cold pressor test. The hyper-reactivity of 13 volunteer (72.22%) converted to hypo reactivity after the Hasya Yoga therapy (combination of laughter and Bhastrika Pranayam) of 6 weeks. Other parameters like basal blood pressure, a rise in blood pressure after cold pressor test, pulse rate, Rate Pressure Product (RPP) and Mean Arterial Pressure (MAP) were also statistically significantly reduced. Regular practice of Hasya Yoga significantly reduces the values of basal blood pressure, cardiovascular hyper-reactivity to blood pressure after one minute of cold stress, heart rate, rate pressure product & MAP after 6 weeks of yoga practice. Laughter is one of our best defenses against stress, and it is important that we find ways to laugh more to cope with stress and remain healthy in the modern world. Laughter Yoga is a perfect way to laugh and get exercise at the same time. Other non-pharmacological methods like meditation, diet, weight reduction and life style modification should also be encouraged to control the modifiable risk factors.
KEYWORDS stress, hasya yoga, bhastrika pranayama, cold pressor test
REFERENCES
1.Li AW, Goldsmith CA. The effects of yoga on anxiety and stress.Altern Med Rev. 2012;17(1):2–35.
2.Julian F, Thayer SS, Yamam JF, Brosschot. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Intl J Cardiol. 2010;141(2):122–131.
3.Cannon WG, De LaPaz D. Emotional stimulation of adrenal secretion. Am J Physiol. 1911;28:64–70.
4.Nagendr HR, Nagaratna R. New perspective in stress management, 3rd Edn. Vivekanand Kendra Yoga Anusandhan Sansthan.1994.
5.Hines EA Jr, Brown GE. A standard stimulus for measuring vasomotor reactions; its application in the study of hypertension. Proc Staff Meet Mayo Clin. 1932;7:332–335.
6.Mourot M, Bouhaddi J, Regnard J. Effects of the cold pressor test on cardiac autonomic control in normal subjects. Physiol Res.2009;58:83–91.
7.Iyengar BKS. Light on yoga: 7th ed. Harpercollins Publishers;New Delhi 2002.
8.Madanmohan, Rai UC, Balavittal V, Thombre DP, Swami Gitananda. Cardiorespiratory changes during savitripranayam and shavasan. The Yoga Review. 1983;3:25–34.
9.Rai UC, Madanmohan, Subramanian N, Swami Gitananda.Oxygen consumption and ventilatory changes during Savitripranayam and Shavasan. J Res Edit Indian Med. 1982;1:23–26.
10.Gopal KS, Anantharaman V, Balachander S, Nishith SD.The cardiorespiratory adjustments in pranayama with and without bandhas in vajrasana. Indian J Med Sci. 1973;27:686–692.
11.Pal GK, Velkumary S, Madanmohan. Effect of short term breathing exercises on the autonomic functions in normal human volunteers.Indian J Med Res. 2004;120:115–121.
12.Mohsen Y, Mojtaba E, Saeid P, FirouzKhaledi. The effect of laughter Yoga on general health among nursing students. Iran J Nurs Midwifery Res. 2014; 19(1):36–40.
13.Chaya MS, Kataria M, Nagendra R. The effects of hearty extended unconditional (HEU) laughter using laughter yoga techniques on physiological, psychological, and immunological parameters in the workplace: a randomized control trial. American Society of Hypertension, Annual Meeting; May 14, 2008; New Orleans, LA.
14.Perloff D, Grim C, Flack J, Frohlich ED, Hill M, McDonald M,Morgenstern BZ. Human blood pressure determination by sphygmomanometer. Circulation. 1993;88:2460–2470.
15.Pal GK, Pravati Pal. Text Book of Practical Physiology, 2nd Edition,Orient Longman (India) Pvt. Ltd 2005.
16.Hines EA, Brown GE. Cold pressor test for measuring the reactibility of blood pressure. Am Heart J. 1936;11:1–9
17.Gharote ML. Effect of yogic training on physical fitness. Yoga Mimansa. 1973;15:31–35.
18.Gopal KC, Bhatnagar OP, Subramanian N, Nishith SD. Effect of yogasanas & pranayamas on blood pressure, pulse rate & some respiratory functions. Indian J Physiol Pharmacol.1973;17(3):273–276.
19.Vyas R, Dikshit N. Effect of meditation on respiratory system, cardiovascular system and lipid profile. Indian J Physiol Pharmacol. 2002;46(4):487–491.
20.Udupa K, Madanmohan, Bhavanani AB, Vijayalakshmi P, Krishnamurthy N. Effect of pranayam training on cardiac function in normal young volunteers. Indian J Physiol. Pharmacol.2003;47(1):27–33.
21.Gobel FL, Nordstrom LA, Nelson RR, Jorgensen CR, Wang Y. The rate-pressure-product as an index of myocardial oxygen consumption during exercise in patients with angina pectoris.Circulation. 1978;57:549–556.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Review article
Mohamed1*, Tariq Abdul Razak2,Rosnani Hashim3
1 Kuliyyah of Pharmacy, International Islamic University Malaysia, Kuantan Campus, Kuantan, Pahang, Malaysia
2Director, International Islamic University Malaysia, Kuantan Campus, Kuantan,Pahang, Malaysia
3 Faculty of Pharmacy, Cyberjaya University College of Medical Sciences, Selangor,Malaysia
Address reprint requests to:
*Dr. Sahimi Mohamed,
Kuliyyah of Pharmacy, International Islamic University Malaysia, Kuantan Campus,25200 Kuantan, Pahang, Malaysia.
Tel: +6016 6661726,Fax: +609-5148442
Article citation: Mohamed S,Razak TA, Hashim R. Development of knowledge of anticoagulant questionnaire: a narrative literature review. J Pharm Biomed Sci 2016;06(09):526–533.Available at www.jpbms.info
ABSTRACT
Background In almost a decade, no new instrument has been developed to assess the knowledge of anticoagulant (KAC) since the validation of knowledge of anticoagulant questionnaire (KAC-Q). Therefore, this study aimed to develop a new instrument to measure KAC among the Malaysian population.
Methods The items for the new KAC-Q were developed based on the narrative literature review and focus group discussion. The Delphi Method was used to assess the content validity of the new KAC-Q. Fifteen experts were involved in three phases of the Delphi survey. The face validity was examined to ensure that the items in the questionnaire were understood by the targeted patients.
Results A total of 37 articles were found to be related to KAC. Almost 100 questions were compiled and categorized into nine domains. After three phases of the Delphi survey, 71 questions were deleted due to similar meaning, irrelevant and unsuitable to be used among the Malaysian population. Of the 29 questions retained, one question was deleted after the face validity test.
Conclusion The completeness and relevance of the KAC-Q as well as the meaning of each individual question were assessed through the content and face validity. With a good structured and adequate information, these 28 KAC-Q questions were considered to have good content and face validity. However, further psychometric testing is needed to ensure that KAC-Q is reliable and valid to aid health care providers in determining patients’ anticoagulant knowledge in targeted populations.
KEYWORDS anticoagulant, content validity, development, knowledge
REFERENCES
1.Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ. Evidence-based management of anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest J. 2012;141: suppl2:e152S–84S.
2.Brown TM, Siu K, Walker D, Pladevall-Vila M, Sander S, Mordin M. Development of a conceptual model of adherence to oral anticoagulants to reduce risk of stroke in patients with atrial fibrillation. J Manag Care Pharm. 2012;18:351–362.
3.Kneeland PP, Fang MC. Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence.2010;24:51–60.
4.Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123:638–645.
5.Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Use and effectiveness of warfarin in medicare beneficiaries with atrial fibrillation. Stroke. 2006;37:1070–1074.
6.Nasser S, Mullan J, Bajorek B. Challenges of older patients’ knowledge about warfarin therapy. J Prim Care Community Health. 2012;3:65–74.
7.Matalqah LM, Radaideh KM, Sulaiman SAS, Hassali MA, Abdul Kader MAS. Relationship between patients’ warfarin knowledge and anticoagulation control: results of a validated tool in Malaysia. J Pharm Biomed Sci. 2013;30:967–974.
8.Van Damme S, Van Deyk K, Budts W, Verhamme P, Moons P.Patient knowledge of and adherence to oral anticoagulation therapy after mechanical heart-valve replacement for congenital or acquired valve defects. Hear Lung J Acute Crit Care.2011;40:139–146.
9.Farsalinos k, Trikilis I, Spyrou A, Savvopoulou M, Kostopoulou A,Livanis E, et al. Comparison of knowledge level about anticoagulation therapy between atrial fibrillation and prosthetic heart valve patients and its’ relation to INR goal attainment. J Am Coll Cardiol. 2012;59:E1701.
10.Tang EO, Lai CS, Lee KK, Wong RS, Cheng G, Chan TY. Relationship between patients ‘warfarin knowledge and anticoagulation control. Ann Pharmacother. 2003;37:34–39.
11.Barcelona D, Marongiu F, Contu P. Patient education and oral anticoagulant therapy. Haematol J. 2002;87:1081–1086.
12.Nutescu EA, Wittkowsky AK, Burnett A, Merli GJ, Ansell JE,Garcia DA. Delivery of optimized inpatient anticoagulation therapy: consensus statement from the anticoagulation forum. Ann Pharmacother. 2013;47:714–724.
13.Clarkesmith DE, Pattison HM, Lip GY, Lane DA. Educational intervention improves anticoagulation control in atrial fibrillation patients: The TREAT randomised trial. PLoS One. 2013;8:e74037.
14.Clark CM, Bayley EW. Evaluation of the use of programmed instruction for patients maintained on Warfarin therapy. Am J Public Health. 1972;62:1135–1139.
15.El-naby AGA, Hashem HY, Ismail GM. Evaluation of a designed warfarin educational program on patients ’ knowledge and incidence of side effects. Glob J Pharmacol. 2014;8:592–600.
16.Wong PY, Schulman S, Woodworth S, Holbrook A. Supplemental patient education for patients taking oral anticoagulants: systematic review and meta-analysis. J Thromb Haemost. 2013;11:491–502.
17.Deck ED. The effect of an educational intervention on oral anticoagulation therapy knowledge in primary care. [dissertation]. Evidence-based practice project reports. Paper 72. 2015.
18.Matalaqah LM, Radaideh K, Hassali MA. An instrument to measure anticoagulation knowledge among Malaysian community: A translation and validation study of the Oral Anticoagulation Knowledge (OAK) Test. Asian J Biomed Pharm Sci. 2013;3:30–37.
19.Baker JW, Pierce KL, Ryals CA. INR goal attainment and oral anticoagulation knowledge of patients enrolled in an anticoagulation clinic in a Veterans Affairs medical center. J Manag Care Pharm. 2011;17:133–142.
20.Wofford JL, Wells MD, Singh S. Best strategies for patient education about anticoagulation with warfarin: a systematic review. BMC Health Serv Res. 2008;8:40.
21.Zeolla MM, Brodeur MR, Dominelli A. Haines ST, Allie ND.Development and validation of an instrument to determine patient knowledge: the oral anticoagulation knowledge test. Ann Pharmacother. 2006;40:633–638.
22.Briggs AL, Jackson TR, Bruce S, Shapiro NL. The development and performance validation of a tool to assess patient anticoagulation knowledge. Res Social Adm Pharm. 2005;1:40–59.
23.Taylor FC, Ramsay ME, Tan G, Gabbay J, Cohen H. Evaluation of patients’ knowledge about anticoagulant treatment. Qual Heal Care. 1994;3:79–85.
24.Smith M. B, Christensen N, Wang S, Strohecker J, Day JD, Weiss JP, et al. Warfarin knowledge in patients with atrial fibrillation: implications for safety, efficacy, and education strategies. Cardiology. 2010;116:61–69.
25.Yahaya AH, Hassali MA, Awaisu A, Shafie AA. Factors associated with warfarin therapy knowledge and anticoagulation control among patients attending a Warfarin Clinic in Malaysia. J Clin Diagnostic Res. 2009;3:1663–1670.
26.Lip GY, Lane DA, Ponsford J, Shelley A, Sirpal A. Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme. The West Birmingham Atrial Fibrillation Project. Int J Cardiol. 2006;110:354–358.
27.Nadar S, Begum N, Kaur B, Sandhu S, Lip GY. Patients’ understanding of anticoagulant therapy in a multiethnic population. J R Soc Med. 2003;96:175–179.
28.St-Louis L, Robichaud-Ekstrand S. Knowledge level and coping strategies according to coagulation levels in older persons with atrial fibrillation. Nurs Health Sci. 2003;5:67–75.
29.Rocha HT, Rabelo ER, Aliti G, de Souza EN. Knowledge of patients with mechanical valve prostheses concerning chronic oral anticoagulant therapy. Rev Lat Am Enfermagem.2010;18:696–702.
30.Janoly-Duménil A, Bourne C, Loiseau K, Luauté J, Sancho PO,Ciancia S, et al. Oral anticoagulant treatment - evaluating the knowledge of patients admitted in physical medicine and rehabilitation units. Ann Phys Rehabil Med. 2011;54:172–180.
31.Wang Y, Kong MC, Lee LH, Ng HJ, Ko Y. Knowledge, satisfaction, and concerns regarding warfarin therapy and their association with warfarin adherence and anticoagulation control. Thromb Res. 2014;133:550–554.
32.Rewiuk K, Bednarz S, Faryan P, Grodzicki T. Knowledge of antithrombotic prophylaxis among patients with atrial fibrillation. Cardiol J. 2007;14:44–49.
33.Davis NJ, Billett HH, Cohen HW, Arnsten JH. Impact of adherence,knowledge, and quality of life on anticoagulation control. Ann Pharmacother. 2005;39:632–636.
34.Collins S, Barber A, Sahm LJ. Pharmacist’s counselling improves patient knowledge regarding warfarin, irrespective of health literacy level. J Pharm. 2014;2:114–123.
35.Voller H, Dovifat C, Glatz J, Körtke H, Taborski U, Wegscheider K. Self management of oral anticoagulation with the IN Ratio system: Impact of a structured teaching program on patient’s knowledge of medical background and procedures. Eur J Cardiovasc Prev Rehabil. 2004;11:442–447.
36.Hu A, Chow C, Dao D, Errett L, Keith M. Factors influencing patient knowledge of warfarin therapy after mechanical heart valve replacement. J Cardiovasc Nurs. 2006;21:169–175.
37.Hasan SS, Shamala R, Syed IA, Basariah N, Chong DW, Mei TK, et al. Factors affecting warfarin-related knowledge and INR control of patients attending physician- and pharmacist-managed anticoagulation clinics. J Pharm Pract. 2011;24:485–493.
38.Chenot JF, Hua TD, Abu Abed M, Schneider-Rudt H, Friede T,Schneider S, et al. Safety relevant knowledge of orally anticoagulated patients without self-monitoring: a baseline survey in primary care. BMC Fam Pract. 2014;15:104.
39.Khudair IF, Hanssens YI. Evaluation of patients’ knowledge on warfarin in outpatient anticoagulation clinics in a teaching hospital in Qatar. Saudi Med J . 2010;3:672–677.
40.Bounda GA, Ngarambe C, Ge WH, Yu F. Assessment and evaluation efficacy of a clinical pharmacist ‑ led inpatient warfarin knowledge education program and follow up at a Chinese tertiary referral teaching hospital. Arch Pharm Pract. 2013;4:168.
41.Fairbairn-Smith L, Cope W, Robinson B, Kamali F, Wynne H. Effect of provision of the NHSNPSA oral anticoagulant therapy patient information pack upon patients’ knowledge and anticoagulant control. J Thromb Haemost. 2011;9:231–233.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Acknowledgement: We gratefully acknowledge the Director General of Health, Malaysia for granting us the permission to publish this study and Hospital Tengku Ampuan Afzan (HTAA). We would also like to thank all the patients, expert panel members, pharmacists and other health care providers managing the W-MTAC at HTAA.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research.
All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Case Report
Nishi Tandon1, Neema Tiwari1, Nirupama Lal1,Vibhore Mahendru2
1Department of Pathology, Eras Lucknow Medical College and Hospital (ELMCH), Lucknow, India
2Department of Surgery, Eras Lucknow Medical College and Hospital (ELMCH), Lucknow, India
Address reprint request to:
*Dr. Neema Tiwari, Resident, Department of Pathology, Eras Lucknow Medical College and Hospital (ELMCH), Lucknow, India
Article citation: Tandon N, Tiwari N, Lal N, Mahendru V Inguinal Sarcoidosis – An Unusual Presentation Journal of Pharmaceutical and Biomedical Sciences. 2016; 06(09):534-536.
REFERENCES
1.Jim George, Reese Graves, Robert Meador. Inguinal lymphadenopathy as the initial presentation of sarcoidosis. Proc (Bayl Univ Med Cent). 2013;26(2):161–162.
2.Nathan MP, Pinsker R, Chase PH, Elguezabel A. Sarcoidosis presenting as lymphedema. Arch Dermatol. 1974;109(4):543–544.
3.Silver HM, Tsangaris NT, Eaton OM. Lymphedema and lymphography in sarcoidosis. Arch Intern Med. 1966;117(5):712–714.
4.Tedavi Edilen Sarkoidoz. Sarcoidosis presenting with inguinal lympadenopathy and treated with a combination of corticosteroids and aazothioprine. Turk J Rheumatol. 2012;27(3):212-213.
5.Chen ES, Moller DR; Medscape. Sarcoidosis-scientific progress and clinical challenges. Nat Rev Rheumatol. 2011;7:457-67. doi: 10.1038/nrrheum.2011.93.
6.Halil Yanardag, Metin Caner, Irfan Papila, Sedat Uygun, Sabriye Demirci, Tuncer Karayel. Diagnostic value of peripheral lymph node biopsy in sarcoidosis: A report of 67 cases. Can Respir J. 2007;4:209–211.
7.Newman LS, Rose CS, Maier LA. Sarcoidosis. New Engl J Med.1997;336:1226-–34. (Erratum in 1997;337:139).
8.James DG. Lymphoreticular involvement. In: James DG, ed. Sarcoidosis and Other Granulomatous Disorders. New York: Marcel.Dekker, 1994:345–347.
9.Stirling RG, Cullinan P, Du Bois RM. Sarcoidosis. In: Schwarz M, King T, eds. Intestinal Lung Disease. Hamilton: BC Dekker Inc, 1988:279–323.
10.Muller- Quernheim J. Sarcoidosis: Immunopathogenic concepts and their clinical application. Eur Respir J. 1998;12:716–738.
11.Torrington KG, Shorr AF, Parker JW. Endobronchial disease and racial differences in pulmonary sarcoidosis. Chest. 1997;111:619–622.
12.DeRemee RA. The roentgenographic staging of sarcoidosis. Historic and contemporary perspectives. Chest. 1983;83:128–133.
Source of funding: None.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Majority of the information gathered are from media sources which don’t reflect the author’s own opinion.
Copyright © 2016 Tandon N, Tiwari N, Lal N, Mahendru V. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article
Suseela Kumari Pamu*,Lavanya Kollapu
Department of Microbiology, Rangaraya Medical College, GGH Campus Kakinada, Andhrapradesh, India
Address reprint requests to:
*Dr. Suseela Kumari Pamu, Department of Microbiology, Rangaraya Medical College, GGH Campus, Kakinada, Andhrapradesh–533001, India
Article citation: Pamu SK, Kollapu L.Isolation of ß-haemolytic streptococci and grouping by enzymatic extraction.J Pharm Biomed Sci 2016;06(09):518–521.
Abstract
Streptococcus pyogenes (group A streptococcus) is one of the most common and ubiquitous human pathogen. It causes invasive and non-invasive human disease. The group A streptococcus infection can be further complicated by non-suppurative sequelae,
such as rheumatic fever, which usually follows throat infection and glomerulonephritis. A total number of 215 children screened for β-haemolytic streptococci from throat swabs and all culture positives are grouped by enzymatic extraction method and ASO estimation was done. All results were analysed statistically. Out of the 215 throat swabs 22.5% positive for β-haemolytic streptococci and grouped as group A 56.5% group C 31.1% group G 13.4%. All culture positives are sensitive to bacitracin 0.04 units and ASO estimated 54%. The proportion of antibiotic sensitivity was high for penicillin, vancomycin, cefotaxime and erythromycin, and the relative resistance to ampicillin and amoxicillin was seen. Our study suggests that the inappropriate use of antibiotic leads to drug resistance.
KEYWORDS β-haemolytic, streptococcal grouping, ASO, bacitracin sensitivity.
REFERENCES
1.Begovac J. Asymptomatic pharyngeal L carriage of beta-hemolytic streptococcus in J Croatia. Principle and practice of infectious disease. 3rd Edn., Churchill-Livingston Ltd. Philadelphia,1990;15–23.
2.Shet A, Kaplan E. Addressing the burden of group A streptococcal disease in India. Indian J Pediatr. 2004;71:41–48.
3.Carapetis JR. The current evidence for the burden of group A streptococcal diseases. World Health Organization 2005.Available at http://www.who.int/ child-adolescent health / New publications/CHILD_HEALTH/DP/WHO_FCH_CA_05.07pdf.
4.A text book of medical microbiology, Greenwood; Eighteenth edition 2012; part III Chapter 16: page no 187.
5.Menon T, Shanmugasundaram S, Kumar MP, Kumar CP. Group A streptococcal infections of the pharynx in a rural population in south India. Indian J Med Res. 2004;119(suppl):171–173.
6.Rammelkamp CH Jr. Epidemiology of Streptococcal infections.Harvey lect. 1957;51:113-142.
7.Bisno AL. Non-suppurative poststreptococcal sequelae: Rheumatic fever and glomerulonephritis. Vol. 2: Churchill Livingston Ltd. New York. N. Y. 1995.
8.Centor RM, Rvoff GE. Sore throat: streptococcal or not? Pediatr Care 1987;21:28–63.
9.Nandi S, Kumar R, Ray P, Vohra H, Ganguly NK. Group A streptococcal sore throat in a periurban population of Northern India: a one-year prospective study. Bull World Health Organ.2001;79:528–533.
10.Johnson DR, Kalpan E, Sramck J, Bicoava R, Havlicek J, Havalickova H, et al. Laboratory methods for the diagnosis of group A streptococcal infections: World Health Organization, Geneva, Switzerland; 1996.
11.Maxted WR. The use of bacitracin for identifying V J group A haemolytic streptococci. J Clin Pathol. 1953;6:224–226.
12.Levinson ML, Frank PF. Differentiation of group A from other beta hemolytic streptococci with bacitracin. J Bacteriol. 1955;69:284–287.
13.Edrerer GM, Hermann MM, Bruce R, Masten JM, Chapman SS. Rapid extraction method with pronase B for grouping beta hemolytic a streptococci. Appl Microboil. 1972;23:285–288.
14.Coleman DJ, McGhie D, Tebutt GM. Further studies on the reliability of the bacitarcin inhibition test for the presumptive identification of Lancefield Group A streptococci. J Clin Pathol.1977;30:421–426.
15.Pollock HM, Dahlgren BJ. Distribution of streptococcal groups in clinical specimens with evaluation of bacitracin screening. Appl Microbiol. 1974;27:141–143.
16.Waunmaker LW, Ayoub EM. Antibody titers in accute rheumatic fever. Circulation. 1960;21:598–614.
17.Ozturk CE, Yavuz T, Kaya D, Yucel M. The rate of asymptomatic throat carriage of group A streptococcus in school children and associated ASO titers in Duzce, Turkey. Jpn J Infect Dis.2004;57:271–272.
18.Navaneeth BV, Ray N, Chawda S, Selvarani P, Bhaskar M, Suganthi N. Prevelence of beta hemolytic streptococcus carrier rate among schoolchildren in Salem. Indian J Pediatr. 2001;68:985–986.
Statement of originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None.
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.